Therefore, RPS6KA2 may play a role in two ways: on the one hand, it may promote endothelial cell angiogenesis, and on the other hand, it may promote the progression of malignant epithelial cells by activating the KRAS signaling pathway; on the other hand, in diabetic patients, hyperglycemia and inflammation trigger endothelial dysfunction, which may eventually lead to vascular remodeling and renal damage (58). Here, RPS6KA2 is linked to endothelial dysfunction.